The role of antibody-dependent enhancement in dengue vaccination.
Journal
Tropical diseases, travel medicine and vaccines
ISSN: 2055-0936
Titre abrégé: Trop Dis Travel Med Vaccines
Pays: England
ID NLM: 101674442
Informations de publication
Date de publication:
01 Nov 2024
01 Nov 2024
Historique:
received:
28
03
2024
accepted:
31
07
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Dengue is the most rapidly spreading vector-borne disease worldwide, with over half the global population at risk for an infection. Antibody-dependent enhancement (ADE) is associated with increased disease severity and may also be attributable to the deterioration of disease in vaccinated people. Two dengue vaccines are approved momentarily, with more in development. The increasing use of vaccines against dengue, combined with the development of more, makes a thorough understanding of the processes behind ADE more important than ever. Above that, due to the lack of treatment options, this method of prevention is of great importance. This review aims to explore the impact of ADE in dengue vaccinations, with the goal of enhancing potential vaccination strategies in the fight against dengue.
Identifiants
pubmed: 39482727
doi: 10.1186/s40794-024-00231-2
pii: 10.1186/s40794-024-00231-2
doi:
Types de publication
Journal Article
Langues
eng
Pagination
22Informations de copyright
© 2024. The Author(s).
Références
Scientific Working Group on Dengue. Meeting (2006: Geneva S, diseases UWBWSPfRaTiT. Report of the Scientific Working Group meeting on Dengue, Geneva, 1–5 October 2006. Report on dengue. Geneva: World Health Organization; 2007.
Messina JP, Brady OJ, Golding N, Kraemer MUG, Wint GRW, Ray SE, et al. The current and future global distribution and population at risk of dengue. Nat Microbiol. 2019;4(9):1508–15.
pubmed: 31182801
pmcid: 6784886
doi: 10.1038/s41564-019-0476-8
Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358(6365):929–32.
pubmed: 29097492
pmcid: 5858873
doi: 10.1126/science.aan6836
Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. Efficacy and long-term safety of a Dengue Vaccine in regions of Endemic Disease. N Engl J Med. 2015;373(13):1195–206.
pubmed: 26214039
doi: 10.1056/NEJMoa1506223
Ooi EE, Kalimuddin S. Insights into dengue immunity from vaccine trials. Sci Transl Med. 2023;15(704):eadh3067.
pubmed: 37437017
doi: 10.1126/scitranslmed.adh3067
Monsalvo AC, Batalle JP, Lopez MF, Krause JC, Klemenc J, Hernandez JZ, et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med. 2011;17(2):195–9.
pubmed: 21131958
doi: 10.1038/nm.2262
Halstead SB, O’Rourke EJ. Dengue viruses and mononuclear phagocytes. I. infection enhancement by non-neutralizing antibody. J Exp Med. 1977;146(1):201–17.
pubmed: 406347
pmcid: 2180729
doi: 10.1084/jem.146.1.201
Schlesinger JJ, Brandriss MW. Antibody-mediated infection of macrophages and macrophage-like cell lines with 17D-yellow fever virus. J Med Virol. 1981;8(2):103–17.
pubmed: 7299376
doi: 10.1002/jmv.1890080204
Peiris JS, Porterfield JS. Antibody-dependent plaque enhancement: its antigenic specificity in relation to Togaviridae. J Gen Virol. 1982;58(Pt 2):291–6.
pubmed: 6174682
doi: 10.1099/0022-1317-58-2-291
Wang SF, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 2014;451(2):208–14.
pubmed: 25073113
pmcid: 7092860
doi: 10.1016/j.bbrc.2014.07.090
Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q et al. Molecular mechanism for antibody-dependent enhancement of Coronavirus Entry. J Virol. 2020;94(5).
Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol. 2003;77(13):7539–44.
pubmed: 12805454
pmcid: 164833
doi: 10.1128/JVI.77.13.7539-7544.2003
Robinson WE, Montefiori DC, Mitchell WM. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet. 1988;1(8589):790–4.
pubmed: 2895317
doi: 10.1016/S0140-6736(88)91657-1
Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422–34.
pubmed: 4305198
doi: 10.1093/oxfordjournals.aje.a120955
Fulginiti VA, Eller JJ, Downie AW, Kempe CH. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA. 1967;202(12):1075–80.
pubmed: 6072745
doi: 10.1001/jama.1967.03130250057008
Halstead SB. Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol Spectr. 2014;2(6).
Kraemer MU, Sinka ME, Duda KA, Mylne AQ, Shearer FM, Barker CM, et al. The global distribution of the arbovirus vectors aedes aegypti and ae. Albopictus. Elife. 2015;4:e08347.
pubmed: 26126267
pmcid: 4493616
doi: 10.7554/eLife.08347
Zatta M, Brichler S, Vindrios W, Melica G, Gallien S. Autochthonous Dengue Outbreak, Paris Region, France, September-October 2023. Emerg Infect Dis. 2023;29(12):2538–40.
pubmed: 37967048
pmcid: 10683815
doi: 10.3201/eid2912.231472
Lenharo M. Dengue is breaking records in the Americas - what’s behind the surge? Nature. 2023.
Codeco CT, Oliveira SS, Ferreira DAC, Riback TIS, Bastos LS, Lana RM, et al. Fast expansion of dengue in Brazil. Lancet Reg Health Am. 2022;12:100274.
pubmed: 36776428
pmcid: 9904033
Du M, Jing W, Liu M, Liu J. The global trends and Regional differences in Incidence of Dengue Infection from 1990 to 2019: an analysis from the global burden of Disease Study 2019. Infect Dis Ther. 2021;10(3):1625–43.
pubmed: 34173959
pmcid: 8234762
doi: 10.1007/s40121-021-00470-2
Yang X, Quam MBM, Zhang T, Sang S. Global burden for dengue and the evolving pattern in the past 30 years. J Travel Med. 2021;28(8).
Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, et al. The global burden of dengue: an analysis from the global burden of Disease Study 2013. Lancet Infect Dis. 2016;16(6):712–23.
pubmed: 26874619
pmcid: 5012511
doi: 10.1016/S1473-3099(16)00026-8
Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7.
pubmed: 23563266
pmcid: 3651993
doi: 10.1038/nature12060
Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: a systematic analysis. Lancet Infect Dis. 2016;16(8):935–41.
pubmed: 27091092
doi: 10.1016/S1473-3099(16)00146-8
Rueda LM, Patel KJ, Axtell RC, Stinner RE. Temperature-dependent development and survival rates of Culex quinquefasciatus and Aedes aegypti (Diptera: Culicidae). J Med Entomol. 1990;27(5):892–8.
pubmed: 2231624
doi: 10.1093/jmedent/27.5.892
Delatte H, Gimonneau G, Triboire A, Fontenille D. Influence of temperature on immature development, survival, longevity, fecundity, and gonotrophic cycles of Aedes albopictus, vector of chikungunya and dengue in the Indian Ocean. J Med Entomol. 2009;46(1):33–41.
pubmed: 19198515
doi: 10.1603/033.046.0105
Watts DM, Burke DS, Harrison BA, Whitmire RE, Nisalak A. Effect of temperature on the vector efficiency of Aedes aegypti for dengue 2 virus. Am J Trop Med Hyg. 1987;36(1):143–52.
pubmed: 3812879
doi: 10.4269/ajtmh.1987.36.143
Murray NE, Quam MB, Wilder-Smith A. Epidemiology of dengue: past, present and future prospects. Clin Epidemiol. 2013;5:299–309.
pubmed: 23990732
pmcid: 3753061
SABIN AB. Research on dengue during World War II. Am J Trop Med Hyg. 1952;1(1):30–50.
pubmed: 14903434
doi: 10.4269/ajtmh.1952.1.30
Tsheten T, Clements ACA, Gray DJ, Adhikary RK, Furuya-Kanamori L, Wangdi K. Clinical predictors of severe dengue: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10(1):123.
pubmed: 34627388
pmcid: 8501593
doi: 10.1186/s40249-021-00908-2
Gupta E, Dar L, Kapoor G, Broor S. The changing epidemiology of dengue in Delhi, India. Virol J. 2006;3:92.
pubmed: 17083743
pmcid: 1636631
doi: 10.1186/1743-422X-3-92
Vinodkumar CS, Kalapannavar NK, Basavarajappa KG, Sanjay D, Gowli C, Nadig NG, Prasad BS. Episode of coexisting infections with multiple dengue virus serotypes in central Karnataka, India. J Infect Public Health. 2013;6(4):302–6.
pubmed: 23806706
doi: 10.1016/j.jiph.2013.01.004
Dengue. Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition. 2009.
Cobra C, Rigau-Pérez JG, Kuno G, Vorndam V. Symptoms of dengue fever in relation to host immunologic response and virus serotype, Puerto Rico, 1990–1991. Am J Epidemiol. 1995;142(11):1204–11.
pubmed: 7485067
doi: 10.1093/oxfordjournals.aje.a117579
World Health Organization. Dengue haemorrhagic fever: diagnosis, treatment, prevention, and control. 2nd ed. Geneva: World Health Organization. 1997. viii, 84 p. p.
Kularatne SA, Dalugama C. Dengue infection: global importance, immunopathology and management. Clin Med (Lond). 2022;22(1):9–13.
pubmed: 35078789
doi: 10.7861/clinmed.2021-0791
Tayal A, Kabra SK, Lodha R. Management of Dengue: an updated review. Indian J Pediatr. 2023;90(2):168–77.
pubmed: 36574088
doi: 10.1007/s12098-022-04394-8
Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis. 2010;10(10):712–22.
pubmed: 20883967
pmcid: 3057165
doi: 10.1016/S1473-3099(10)70166-3
Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013;158(7):1445–59.
pubmed: 23471635
doi: 10.1007/s00705-013-1645-3
O’Driscoll M, Buddhari D, Huang AT, Waickman A, Kaewhirun S, Iamsirithaworn S, et al. Maternally derived antibody titer dynamics and risk of hospitalized infant dengue disease. Proc Natl Acad Sci U S A. 2023;120(41):e2308221120.
pubmed: 37774093
pmcid: 10576102
doi: 10.1073/pnas.2308221120
Bournazos S, Gupta A, Ravetch JV. The role of IgG fc receptors in antibody-dependent enhancement. Nat Rev Immunol. 2020;20(10):633–43.
pubmed: 32782358
pmcid: 7418887
doi: 10.1038/s41577-020-00410-0
Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik SK, et al. IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity. Science. 2017;355(6323):395–8.
pubmed: 28126818
pmcid: 5557095
doi: 10.1126/science.aai8128
Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV. Signaling by antibodies: recent progress. Annu Rev Immunol. 2017;35:285–311.
pubmed: 28446061
pmcid: 5613280
doi: 10.1146/annurev-immunol-051116-052433
Wang TT, Maamary J, Tan GS, Bournazos S, Davis CW, Krammer F, et al. Anti-HA Glycoforms Drive B Cell Affinity selection and determine Influenza Vaccine Efficacy. Cell. 2015;162(1):160–9.
pubmed: 26140596
pmcid: 4594835
doi: 10.1016/j.cell.2015.06.026
Bournazos S, Vo HTM, Duong V, Auerswald H, Ly S, Sakuntabhai A, et al. Antibody fucosylation predicts disease severity in secondary dengue infection. Science. 2021;372(6546):1102–5.
pubmed: 34083490
pmcid: 8262508
doi: 10.1126/science.abc7303
Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement System Part I - Molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.
pubmed: 26082779
pmcid: 4451739
doi: 10.3389/fimmu.2015.00262
Janeway CA Jr, Walport TP et al. M,. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001.
Yamanaka A, Kosugi S, Konishi E. Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J Virol. 2008;82(2):927–37.
pubmed: 18003724
doi: 10.1128/JVI.00992-07
Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med. 2002;196(6):859–65.
pubmed: 12235218
pmcid: 2194058
doi: 10.1084/jem.20020781
Byrne AB, Bonnin FA, López EL, Polack FP, Talarico LB. C1q modulation of antibody-dependent enhancement of dengue virus infection in human myeloid cell lines is dependent on cell type and antibody specificity. Microbes Infect. 2024:105378.
Mehlhop E, Nelson S, Jost CA, Gorlatov S, Johnson S, Fremont DH, et al. Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe. 2009;6(4):381–91.
pubmed: 19837377
pmcid: 2782387
doi: 10.1016/j.chom.2009.09.003
Wegman AD, Waldran MJ, Bahr LE, Lu JQ, Baxter KE, Thomas SJ, Waickman AT. DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent enhancement of DENV infection. PLoS Pathog. 2023;19(8):e1011616.
pubmed: 37639455
pmcid: 10491401
doi: 10.1371/journal.ppat.1011616
Sawant J, Patil A, Kurle S. A review: understanding molecular mechanisms of antibody-dependent enhancement in viral infections. Vaccines (Basel). 2023;11(7).
Zhang X, Ge P, Yu X, Brannan JM, Bi G, Zhang Q, et al. Cryo-EM structure of the mature dengue virus at 3.5-Å resolution. Nat Struct Mol Biol. 2013;20(1):105–10.
pubmed: 23241927
doi: 10.1038/nsmb.2463
Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature. 2004;427(6972):313–9.
pubmed: 14737159
doi: 10.1038/nature02165
Lim XX, Chandramohan A, Lim XY, Bag N, Sharma KK, Wirawan M, et al. Conformational changes in intact dengue virus reveal serotype-specific expansion. Nat Commun. 2017;8:14339.
pubmed: 28186093
pmcid: 5309819
doi: 10.1038/ncomms14339
Sattentau QJ, Moore JP. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med. 1991;174(2):407–15.
pubmed: 1713252
doi: 10.1084/jem.174.2.407
Sullivan N, Sun Y, Li J, Hofmann W, Sodroski J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol. 1995;69(7):4413–22.
pubmed: 7769703
pmcid: 189183
doi: 10.1128/jvi.69.7.4413-4422.1995
Ong EZ, Zhang SL, Tan HC, Gan ES, Chan KR, Ooi EE. Dengue virus compartmentalization during antibody-enhanced infection. Sci Rep. 2017;7:40923.
pubmed: 28084461
pmcid: 5234037
doi: 10.1038/srep40923
Modhiran N, Kalayanarooj S, Ubol S. Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapse. PLoS Negl Trop Dis. 2010;4(12):e924.
pubmed: 21200427
pmcid: 3006139
doi: 10.1371/journal.pntd.0000924
Rolph MS, Zaid A, Rulli NE, Mahalingam S. Downregulation of interferon-β in antibody-dependent enhancement of dengue viral infections of human macrophages is dependent on interleukin-6. J Infect Dis. 2011;204(3):489–91.
pubmed: 21742851
doi: 10.1093/infdis/jir271
Ubol S, Chareonsirisuthigul T, Kasisith J, Klungthong C. Clinical isolates of dengue virus with distinctive susceptibility to nitric oxide radical induce differential gene responses in THP-1 cells. Virology. 2008;376(2):290–6.
pubmed: 18455750
doi: 10.1016/j.virol.2008.03.030
Ubol S, Phuklia W, Kalayanarooj S, Modhiran N. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis. 2010;201(6):923–35.
pubmed: 20158392
doi: 10.1086/651018
Chareonsirisuthigul T, Kalayanarooj S, Ubol S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol. 2007;88(Pt 2):365–75.
pubmed: 17251552
doi: 10.1099/vir.0.82537-0
Deng SQ, Yang X, Wei Y, Chen JT, Wang XJ, Peng HJ. A review on Dengue Vaccine Development. Vaccines (Basel). 2020;8(1).
Thomas SJ. Is new dengue vaccine efficacy data a relief or cause for concern? Npj Vaccines. 2023;8(1).
Torres-Flores JM, Reyes-Sandoval A, Salazar MI. Dengue vaccines: an update. Biodrugs. 2022;36(3):325–36.
pubmed: 35608749
pmcid: 9127483
doi: 10.1007/s40259-022-00531-z
Henein S, Swanstrom J, Byers AM, Moser JM, Shaik SF, Bonaparte M, et al. Dissecting antibodies Induced by a chimeric yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in naive and dengue-exposed individuals. J Infect Dis. 2017;215(3):351–8.
pubmed: 27932620
Halstead SB. Is Dengue Vaccine Protection possible? Clin Infect Dis. 2022;74(1):156–60.
pubmed: 33788926
doi: 10.1093/cid/ciab282
Halstead SB, Russell PK, Brandt WE. NS1, Dengue’s Dagger. J Infect Dis. 2020;221(6):857–60.
pubmed: 30783665
Sharma M, Glasner DR, Watkins H, Puerta-Guardo H, Kassa Y, Egan MA, et al. Magnitude and functionality of the NS1-Specific antibody response elicited by a live-attenuated tetravalent dengue vaccine candidate. J Infect Dis. 2020;221(6):867–77.
pubmed: 30783676
doi: 10.1093/infdis/jiz081
Halstead SB. Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge. Am J Trop Med Hyg. 2016;95(4):741–5.
pubmed: 27352870
pmcid: 5062765
doi: 10.4269/ajtmh.16-0222
EMA, Dengvaxia, European Medicine Agency. ; 2023 [updated 11-08-2023. https://www.ema.europa.eu/en/medicines/human/EPAR/dengvaxia
FDA, DENGVAXIA. U.S. Food & Drug Administration; 2023 [updated 08-08-2023. https://www.fda.gov/vaccines-blood-biologics/dengvaxia
Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, O’Brien K, Vannice K, et al. Deliberations of the Strategic Advisory Group of experts on immunization on the use of CYD-TDV dengue vaccine. Lancet Infect Dis. 2019;19(1):e31–8.
pubmed: 30195995
doi: 10.1016/S1473-3099(18)30494-8
Takeda. Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden. and Transmission Areas in Children Ages Six to 16 Years: Takeda Pharmaceuticals; 2023 [updated 03-10-2023. https://www.takeda.com/newsroom/newsreleases/2023/Takeda-Dengue-Vaccine-Recommended-by-World-Health-Organization-Advisory-Group-for-Introduction-in-High-Dengue-Burden-and-Transmission-Areas-in-Children-Ages-Six-to-16-Years/
EMA, Qdenga, European Medicines Agency. ; 2023 [updated 12-04-2023. https://www.ema.europa.eu/en/medicines/human/EPAR/qdenga
Gezondheidsraad H. Vaccinatie tegen dengue: Volksgezondheid, Veiligheid van de Voedselketen, Leefmilieu; 2023 [updated 05-04-2023. https://www.health.belgium.be/nl/advies-9739-vaccinatie-tegen-dengue
Institut RK, Denguefieber. Das Robert Koch-Institut; 2023 [updated 30-11-2023. https://www.rki.de/SharedDocs/FAQ/Dengue/FAQ-Liste.html
Palanichamy Kala M, St John AL, Rathore APS. Dengue: update on clinically relevant therapeutic strategies and vaccines. Curr Treat Options Infect Dis. 2023;15(2):27–52.
pubmed: 37124673
pmcid: 10111087
doi: 10.1007/s40506-023-00263-w
Tricou V, Yu D, Reynales H, Biswal S, Saez-Llorens X, Sirivichayakul C, et al. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Glob Health. 2024;12(2):e257–70.
pubmed: 38245116
doi: 10.1016/S2214-109X(23)00522-3
Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, et al. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and adolescents. N Engl J Med. 2019;381(21):2009–19.
pubmed: 31693803
doi: 10.1056/NEJMoa1903869
Rivera L, Biswal S, Sáez-Llorens X, Reynales H, López-Medina E, Borja-Tabora C, et al. Three-year Efficacy and Safety of Takeda’s Dengue Vaccine candidate (TAK-003). Clin Infect Dis. 2022;75(1):107–17.
pubmed: 34606595
doi: 10.1093/cid/ciab864
ClinicalTrials.gov. Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose: National Library of Medicine; 2023 [updated 14-02-2023. https://clinicaltrials.gov/study/NCT03999996
Kallás EG, Cintra MAT, Moreira JA, Patiño EG, Braga PE, Tenório JCV, et al. Live, attenuated, Tetravalent Butantan-Dengue vaccine in children and adults. N Engl J Med. 2024;390(5):397–408.
pubmed: 38294972
doi: 10.1056/NEJMoa2301790
Walsh MR, Alam MS, Pierce KK, Carmolli M, Alam M, Dickson DM, et al. Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial. Lancet Infect Dis. 2024;24(2):150–60.
pubmed: 37776876
doi: 10.1016/S1473-3099(23)00520-0
Pierce KK, Durbin AP, Walsh MR, Carmolli M, Sabundayo BP, Dickson DM et al. TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies. J Clin Invest. 2024;134(3).
Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328(5979):745–8.
pubmed: 20448183
doi: 10.1126/science.1185181
Screaton G, Mongkolsapaya J, Yacoub S, Roberts C. New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol. 2015;15(12):745–59.
pubmed: 26603900
doi: 10.1038/nri3916
Basheer A, Jamal SB, Alzahrani B, Faheem M. Development of a tetravalent subunit vaccine against dengue virus through a vaccinomics approach. Front Immunol. 2023;14:1273838.
pubmed: 38045699
pmcid: 10690774
doi: 10.3389/fimmu.2023.1273838
Shukla R, Ramasamy V, Shanmugam RK, Ahuja R, Khanna N. Antibody-dependent enhancement: a challenge for developing a safe Dengue Vaccine. Front Cell Infect Microbiol. 2020;10:572681.
pubmed: 33194810
pmcid: 7642463
doi: 10.3389/fcimb.2020.572681
Acosta EG, Bartenschlager R. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development. Expert Rev Vaccines. 2016;15(4):467–82.
pubmed: 26577689
doi: 10.1586/14760584.2016.1121814
Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 2009;392(1):103–13.
pubmed: 19631955
doi: 10.1016/j.virol.2009.06.037
Fernandez E, Dejnirattisai W, Cao B, Scheaffer SM, Supasa P, Wongwiwat W, et al. Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. Nat Immunol. 2017;18(11):1261–9.
pubmed: 28945244
pmcid: 5679314
doi: 10.1038/ni.3849
Mamo T, Poland GA. Nanovaccinology: the next generation of vaccines meets 21st century materials science and engineering. Vaccine. 2012;30(47):6609–11.
pubmed: 23067445
doi: 10.1016/j.vaccine.2012.08.023
Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8 + T cells. Proc Natl Acad Sci U S A. 2013;110(22):E2046–53.
pubmed: 23580623
pmcid: 3670335
doi: 10.1073/pnas.1305227110
Muller DA, Young PR. The flavivirus NS1 protein: molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker. Antiviral Res. 2013;98(2):192–208.
pubmed: 23523765
doi: 10.1016/j.antiviral.2013.03.008
Züst R, Li SH, Xie X, Velumani S, Chng M, Toh YX, et al. Characterization of a candidate tetravalent vaccine based on 2’-O-methyltransferase mutants. PLoS ONE. 2018;13(1):e0189262.
pubmed: 29298302
pmcid: 5751980
doi: 10.1371/journal.pone.0189262
Miauton A, Audran R, Besson J, Maby-El Hajjami H, Karlen M, Warpelin-Decrausaz L, et al. Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study. EBioMedicine. 2024;99:104922.
pubmed: 38128414
doi: 10.1016/j.ebiom.2023.104922
Harapan H, Fajar JK, Sasmono RT, Kuch U. Dengue vaccine acceptance and willingness to pay. Hum Vaccin Immunother. 2017;13(4):786–90.
pubmed: 27905832
doi: 10.1080/21645515.2016.1259045
Hadisoemarto PF, Castro MC. Public acceptance and willingness-to-pay for a future dengue vaccine: a community-based survey in Bandung, Indonesia. PLoS Negl Trop Dis. 2013;7(9):e2427.
pubmed: 24069482
pmcid: 3777870
doi: 10.1371/journal.pntd.0002427
Mendes Lobão W, Duarte FG, Burns JD, de Souza Teles Santos CA, Chagas de Almeida MC, Reingold A, Duarte Moreira EJ. Low coverage of HPV vaccination in the national immunization programme in Brazil: parental vaccine refusal or barriers in health-service based vaccine delivery? PLoS ONE. 2018;13(11):e0206726.
pubmed: 30418980
pmcid: 6231618
doi: 10.1371/journal.pone.0206726
Marchand E, Glenn BA, Bastani R. Low HPV vaccine coverage among female community college students. J Community Health. 2012;37(6):1136–44.
pubmed: 22669623
pmcid: 3747828
doi: 10.1007/s10900-012-9572-x
Thomas SJ, Yoon IK. A review of Dengvaxia
pubmed: 31589551
pmcid: 6816420
doi: 10.1080/21645515.2019.1658503
Preto C, Maron de Mello A, Cesário Pereira Maluf EM, Teixeira Krainski E, Graeff G, de Sousa GA, et al. Vaccination coverage and adherence to a dengue vaccination program in the state of Paraná, Brazil. Vaccine. 2021;39(4):711–9.
pubmed: 33386178
doi: 10.1016/j.vaccine.2020.12.030
Dengue vaccine. WHO position paper, September 2018 - recommendations. Vaccine. 2019;37(35):4848–9.
doi: 10.1016/j.vaccine.2018.09.063
Diaz-Quijano FA, Siqueira de Carvalho D, Raboni SM, Shimakura SE, Maron de Mello A, Vieira da Costa-Ribeiro MC, et al. Effectiveness of mass dengue vaccination with CYD-TDV (Dengvaxia
pubmed: 38807985
pmcid: 11131085
Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, et al. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. N Engl J Med. 2018;379(4):327–40.
pubmed: 29897841
doi: 10.1056/NEJMoa1800820
Meeting of the Strategic Advisory. Group of Experts on Immunization, September 2023: conclusions and recommendations. 2023.